Skip to main content

Table 1 HDACis under clinical development

From: Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia

Chemical structure

Name

Target

Study phase

Hydroxamates

SAHA (vorinostat)

Pan-inhibitor

Phase III alone or in combination

PXD101 (belinostat)

Pan-inhibitor

Phase II alone or in combination

LBH589 (panobinostat)

Pan-inhibitor

Phase II alone or in combination

ITF2357 (givinostat)

Pan-inhibitor

Phase II alone or in combination

4SC-201 (resminostat)

Pan-inhibitor

Phase II alone or in combination

PCI 24781 (abexinostat)

Classes I and II

Phase II alone or in combination

Cyclic peptides

Depsipeptide/FK228 (romidepsin)

Classes I

phase III alone or in combination

Aliphatic fatty acids

Valproic acid

Classes I and IIa

Phase II alone or in combination

Butyrate

Classes I and IIa

Phase II alone or in combination

Benzamides

MS-275 (entinostat)

Class I

Phase II alone or in combination

MGCD0103 (mocetinostat)

Class I/IV

Phase II alone or in combination

  1. HDACis HDAC inhibitors